The application of the pretreatment regimen containing cladribine in relapse and refractory acute myeloid leukemia patients with HLA haploidentical hematopoietic stem cell transplantation

A multicenter, randomized, controlled, open label clinical trial for a conditional regimen containing cladribine for HLA haploidentical hematopoietic stem cell transplantation for relapse and refractory acute myeloid leukemia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023545

Enrollment

Unknown

Registered

2019-06-01

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transplantation preconditioning for acute myeloid leukemia

Interventions

conditionnal regimen containing cladribine:cladribine

control:Non

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Conformity with the diagnostic criteria of relapsed refractory acute myeloid leukemia; 2. Aged 18 to 55 years; 3. Patient ECOG score 0-3; 4. Expected survival > 6 weeks.

Exclusion criteria

Exclusion criteria: 1. Patient has serious organ dysfunction; 2. Patient has leukemia combined with other cancer; 3. Patient presented clinical signs of brain dysfunction or severe mental illness who cant comply with the study protocol; 4. Patient was unable to schedule follow-up.

Design outcomes

Primary

Measure	Time frame
relapse;	—

Secondary

Measure	Time frame
over survival;graft versus hose disease;leukemia free survival;subtype of lymphocyte;	—

Countries

China

Contacts

Public ContactGao Lei

Department of Hematology, Xinqiao Hospital

gaolei7765@163.com+86 13228689635

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026